Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 2Colorectal Neoplasms 2Uveal Melanoma 1Rare Tumor 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1

Interventions

sintilimab 1pyrotinib 1palbociclib 1niraparib 1dacomitinib 1aumolertinib 1atezolizumab 1alectinib 1Vemurafenib 1Imatinib Mesylate 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Rare Tumor × Crizotinib × Clear all
NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
770 enrolled

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡